We are live on ! Find out more
LQDA icon

Liquidia Corp

44 hedge funds and large institutions have $37.4M invested in Liquidia Corp in 2019 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

42% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 12

0% more funds holding

Funds holding: 4444 (0)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

2.39% less ownership

Funds ownership: 58.82%56.43% (-2.4%)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

57% less capital invested

Capital invested by funds: $87.7M → $37.4M (-$50.3M)

Holders
44
Holders Change
Holders Change %
0%
% of All Funds
0.96%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
5
Increased
17
Reduced
12
Closed
5
Calls
Puts
Net Calls
Net Calls Change

LQDA Hedge Fund Activity: Q3 2019 in Review

44 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Liquidia Corp (LQDA) for Q3 2019, worth a combined $37.4M — down 57% from $87.7M a quarter earlier.

Fund positioning in LQDA was balanced in Q3 2019: 5 funds opened new positions, 5 closed out, 17 added to existing stakes and 12 trimmed.

The largest buyer was ArrowMark Colorado Holdings, adding an estimated $1.33M. The largest seller was Samsara BioCapital, cutting an estimated $2.98M.

  • 44 institutional investors held Liquidia Corp (LQDA) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $37.4M of Liquidia Corp stock for Q3 2019, down 57% quarter-over-quarter.
  • 5 funds opened new Liquidia Corp positions in Q3 2019 and 5 closed out, a net change of 0 holders.
  • The largest Liquidia Corp buyer in Q3 2019 was ArrowMark Colorado Holdings, an estimated $1.33M added.
  • The largest Liquidia Corp seller in Q3 2019 was Samsara BioCapital, an estimated $2.98M sold.

Based on aggregated 13F filings for Q3 2019.